These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9499670)

  • 41. Impact of activated protein C resistance on general vascular surgical patients.
    Donaldson MC; Belkin M; Whittemore AD; Mannick JA; Longtine JA; Dorfman DM
    J Vasc Surg; 1997 Jun; 25(6):1054-60. PubMed ID: 9201166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activated protein C resistance caused by factor V gene mutation: common coagulation defect in chronic venous leg ulcers?
    Peus D; Heit JA; Pittelkow MR
    J Am Acad Dermatol; 1997 Apr; 36(4):616-20. PubMed ID: 9092749
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The influence of factor VIII on measurement of activated protein C resistance.
    Laffan MA; Manning R
    Blood Coagul Fibrinolysis; 1996 Nov; 7(8):761-5. PubMed ID: 9034555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protein S deficiency, activated protein C resistance and sticky platelet syndrome in a young woman with bilateral strokes.
    Chaturvedi S; Dzieczkowski JS
    Cerebrovasc Dis; 1999; 9(2):127-30. PubMed ID: 9973658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance to activated protein C and factor V Leiden.
    Perry DJ; Pasi KJ
    QJM; 1997 Jun; 90(6):379-85. PubMed ID: 9205675
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C.
    Press RD; Liu XY; Beamer N; Coull BM
    Stroke; 1996 Jan; 27(1):44-8. PubMed ID: 8553401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ischemic stroke and activated protein C resistance.
    Bachmeyer C; Toulon P; Dhôte R; Christoforov B; Zuber M; Mas JL
    JAMA; 1995 Oct; 274(16):1266. PubMed ID: 7563524
    [No Abstract]   [Full Text] [Related]  

  • 48. Stroke in a neonate heterozygous for factor V Leiden.
    Varelas PN; Sleight BJ; Rinder HM; Sze G; Ment LR
    Pediatr Neurol; 1998 Mar; 18(3):262-4. PubMed ID: 9568926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The factor V Leiden mutation (R506Q) is not a major risk factor for migrainous cerebral infarction.
    Haan J; Kappelle LJ; de Ronde H; Ferrari MD; Bertina RM
    Cephalalgia; 1997 Aug; 17(5):605-7. PubMed ID: 9251878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prenatal stroke in a neonate heterozygous for factor V Leiden mutation.
    Verdu A; Cazorla MR; Moreno JC; Casado LF
    Brain Dev; 2005 Sep; 27(6):451-4. PubMed ID: 16122636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM.
    Gandrille S; Greengard JS; Alhenc-Gelas M; Juhan-Vague I; Abgrall JF; Jude B; Griffin JH; Aiach M
    Blood; 1995 Jul; 86(1):219-24. PubMed ID: 7795227
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activated protein C resistance: What have we learned now that the dust has settled?
    Petäjä JM; Griffin JH
    Ann Med; 1997 Dec; 29(6):469-72. PubMed ID: 9562511
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response to activated protein C and cerebrovascular disease.
    Jones MP; Alving B
    Ann Intern Med; 1997 May; 126(10):832-3. PubMed ID: 9148671
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical and laboratory data in heterozygous factor V Leiden mutation positive versus negative patients with TIA and minor stroke.
    Lalouschek W; Suess E; Aull S; Schnider P; Uhl F; Zeiler K; Pabinger-Fasching I
    Stroke; 1995 Oct; 26(10):1963-4. PubMed ID: 7570761
    [No Abstract]   [Full Text] [Related]  

  • 55. Specificity of an assay based on a factor V-depleted plasma in patients carrying the Arg 506 Gln mutation.
    Alhenc-Gelas M; Aillaud MF; Bonvarlet MN; Dupuy G; Juhan-Vague I; Aiach M
    Thromb Haemost; 1996 Jun; 75(6):976-7. PubMed ID: 8822599
    [No Abstract]   [Full Text] [Related]  

  • 56. Activated protein C resistance and factor V Leiden mutation are risk factors for cerebral sinus thrombosis.
    Siegert CE; Smelt AH; de Bruin TW
    Stroke; 1997 Jun; 28(6):1291-2. PubMed ID: 9183366
    [No Abstract]   [Full Text] [Related]  

  • 57. Factor V Leiden is not responsible for stroke in patients with sickling disorders and is uncommon in African Americans with sickle cell disease.
    Kahn MJ; Scher C; Rozans M; Michaels RK; Leissinger C; Krause J
    Am J Hematol; 1997 Jan; 54(1):12-5. PubMed ID: 8980255
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of the factor VLeiden mutation. Development of a testing algorithm combining a coagulation assay and molecular diagnosis.
    Wasserman LM; Edson JR; Key NS; Chibbar R; McGlennen RC
    Am J Clin Pathol; 1997 Oct; 108(4):427-33. PubMed ID: 9322597
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Resistance to activated protein C (APCR): reference values of APC-ratios for children.
    Uttenreuther-Fischer MM; Ziemer S; Gaedicke G
    Thromb Haemost; 1996 Nov; 76(5):813-4. PubMed ID: 8950795
    [No Abstract]   [Full Text] [Related]  

  • 60. HELLP syndrome associated with factor V R506Q mutation.
    Brenner B; Lanir N; Thaler I
    Br J Haematol; 1996 Mar; 92(4):999-1001. PubMed ID: 8616100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.